This course has expired. View available courses.
Women's Health
Current treatment for women experiencing menopausal symptoms
Menopausal hormone therapy (MHT) can make a significant difference to women experiencing symptoms of menopause. Vasomotor (hot flashes) and genitourinary (vaginal atrophy, genital dryness, burning, irritation, dyspareunia) are the most common symptoms, experienced by up to 80% of women. As many as 25% of these women will seek treatment. Systemic hormone therapy is the most effective treatment for most menopausal symptoms. Bone protection is also an indication for MHT even without vasomotor or other symptoms.
There are several considerations when determining whether treatment is appropriate, and which treatment to choose. Women with no contraindications who are experiencing menopausal symptoms that are impacting QoL may be considered for treatment with MHT. The benefit-risk ratio is most favorable when therapy is initiated with women within 10 years of the last period, and/or under 60 years of age.
This 30-minute accredited program focuses on systemic MHT. It addresses the assessment criteria to determine if a patient is a good candidate for MHT and reviews the current MHT options, reasons to consider switching treatment options, and counselling patients about management of MHT.
Know more by watching Canadian Experts discuss Tibolone in the context of other available tissue-specific estrogen compounds
This program has received an educational grant or in-kind support from BioSyent Pharma Inc.
DURATION
0.5 hr
PROFESSION
Physician
# OF CREDITS
0.5
ACCREDITATION
Mainpro+
EXPIRY DATE
2022-06-14
Menopausal hormone therapy (MHT) can make a significant difference to women experiencing symptoms of menopause. Vasomotor (hot flashes) and genitourinary (vaginal atrophy, genital dryness, burning, irritation, dyspareunia) are the most common symptoms, experienced by up to 80% of women. As many as 25% of these women will seek treatment. Systemic hormone therapy is the most effective treatment for most menopausal symptoms. Bone protection is also an indication for MHT even without vasomotor or other symptoms.
There are several considerations when determining whether treatment is appropriate, and which treatment to choose. Women with no contraindications who are experiencing menopausal symptoms that are impacting QoL may be considered for treatment with MHT. The benefit-risk ratio is most favorable when therapy is initiated with women within 10 years of the last period, and/or under 60 years of age.
This 30-minute accredited program focuses on systemic MHT. It addresses the assessment criteria to determine if a patient is a good candidate for MHT and reviews the current MHT options, reasons to consider switching treatment options, and counselling patients about management of MHT.
Know more by watching Canadian Experts discuss Tibolone in the context of other available tissue-specific estrogen compounds
This program has received an educational grant or in-kind support from BioSyent Pharma Inc.
Faculty
Denise Black, MD, FRCSC
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Susan Goldstein, MD, CCFP, FCFP, NCMP
Marla Shapiro, C.M. MDCM, CCFP, MHSc, FRCPC, FCFP, NCMP
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Select the appropriate patients for systemic menopausal hormone therapy (MHT);
- Review and differentiate between current MHT options;
- Discuss strategies when switching MHT options;
- Counsel patients about the management of MHT.
Accreditation
#
of credits: 0.5
Duration: 0.5 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
0.5 hr
Duration
Physician
Profession
0.5
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Select the appropriate patients for systemic menopausal hormone therapy (MHT);
- Review and differentiate between current MHT options;
- Discuss strategies when switching MHT options;
- Counsel patients about the management of MHT.
Mainpro+
ACCREDITATION
Women's Health
Learning Category
General
Topic
0
Price
2022-06-14
Expiry Date
CAN-eng
Region/Language
Course Description
Menopausal hormone therapy (MHT) can make a significant difference to women experiencing symptoms of menopause. Vasomotor (hot flashes) and genitourinary (vaginal atrophy, genital dryness, burning, irritation, dyspareunia) are the most common symptoms, experienced by up to 80% of women. As many as 25% of these women will seek treatment. Systemic hormone therapy is the most effective treatment for most menopausal symptoms. Bone protection is also an indication for MHT even without vasomotor or other symptoms.
There are several considerations when determining whether treatment is appropriate, and which treatment to choose. Women with no contraindications who are experiencing menopausal symptoms that are impacting QoL may be considered for treatment with MHT. The benefit-risk ratio is most favorable when therapy is initiated with women within 10 years of the last period, and/or under 60 years of age.
This 30-minute accredited program focuses on systemic MHT. It addresses the assessment criteria to determine if a patient is a good candidate for MHT and reviews the current MHT options, reasons to consider switching treatment options, and counselling patients about management of MHT.
Know more by watching Canadian Experts discuss Tibolone in the context of other available tissue-specific estrogen compounds
This program has received an educational grant or in-kind support from BioSyent Pharma Inc.
Faculty
Denise Black, MD, FRCSC
Vivien Brown, MDCM, CCFP, FCFP, NCMP
Susan Goldstein, MD, CCFP, FCFP, NCMP
Marla Shapiro, C.M. MDCM, CCFP, MHSc, FRCPC, FCFP, NCMP
Accreditation
This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ Credit(s).
0.5 hr
Duration
0
Price
0.5
# of credits
